News - Daiichi Sankyo, Oncology

Filter

Current filters:

Daiichi SankyoOncology

Popular Filters

Daiichi Sankyo files Ranmark to treat giant cell tumor of bone in Japan

29-08-2013

Japanese drug major Daiichi Sankyo (TYO: 4568) has filed an application for approval in Japan to manufacture…

AmgenAsia-PacificDaiichi SankyoOncologyPharmaceuticalPraliaRanmarkRegulation

Daiichi Sankyo returns rights to ArQule for global AKT program

03-04-2013

Japanese drug major Daiichi Sankyo (TYO: 4568) has returned worldwide rights for the development and…

ARQ 092ARQ 197ArQuleDaiichi SankyoLicensingOncologyPharmaceuticalResearchtivantinib

Another disappointment with Daiichi Sankyo and ArQule's tivantinib

14-01-2013

US drug developer ArQule (Nasdaq: ARQL) saw its shares plunge 23% to $2.25 in premarket trading on Friday,…

ArQuleDaiichi SankyoOncologyPharmaceuticalResearchtivantinib

Sales of cancer pain therapies set to grow to $5.2 billion in the G7 by 2021

13-12-2012

Sales of cancer pain therapies will increase to $5.2 billion in 2021 in leading seven markets (the USA,…

AmgenBiotechnologyDaiichi SankyodenosumabGlaxoSmithKlineGlobalMarkets & MarketingOncologyPharmaceuticalRanmarkXgeva

ArQule and Daiichi Sankyo drop tivantinib trial in NSCLC

03-10-2012

USA-based drug developer ArQule (Nasdaq: ARQL) saw its shares plunge 62% to $1.90 after, along with its…

ArQuleBiotechnologyDaiichi SankyoOncologyPharmaceuticalResearchtivantinib

Daiichi Sankyo debuts bone cancer drug Ranmark in Japan

17-04-2012

Following National Health Insurance price listing yesterday, Japanese drug major Daiichi Sankyo (TYO:…

AmgenAsia-PacificAstraZenecaBiotechnologyDaiichi SankyodenosumabMarkets & MarketingOncologyPharmaceuticalRanmark

European approval for Roche skin cancer drug Zelboraf

21-02-2012

Swiss drug major Roche (ROG: SIX) says that the European Commission has approved Zelboraf (vemurafenib)…

Daiichi SankyoEuropeOncologyPharmaceuticalRegulationRocheZelboraf

Japanese approval for Regnite and Ranmark

18-01-2012

Japanese drug major Astellas Pharma (TYO: 4503) and USA-based XenoPort (Nasdaq: XNPT) revealed yesterday…

AmgenAsia-PacificAstellas PharmaAstraZenecaBiotechnologyDaiichi SankyodenosumabFinancialNeurologicalOncologyPharmaceuticalRanmarkRegniteRegulationXenoPort

EMA recommends approval of Roche’s Zelboraf

19-12-2011

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended…

Daiichi SankyoEuropeOncologyPharmaceuticalRegulationRocheZelboraf

Backing for Japanese approval of Regnite, Ranmark and Cancidas

05-12-2011

USA-based XenoPort (Nasdaq: XNPT) saw its shares rise 3% to $4.73 on Friday, when the company said it…

Antibiotics and Infectious diseasesAsia-PacificCancidasDaiichi SankyodenosumabHorizantMerck & CoOncologyPharmaceuticalRegniteRegulationXenoPort

Daiichi Sankyo to license ARQ 092 from ArQule, under joint AKIP research collaboration

11-11-2011

Japanese drug major Daiichi Sankyo (TSE 4568) says it has executed a license agreement with USA-based…

ArQuleDaiichi SankyoLicensingOncologyPharmaceuticalResearch

Daiichi Sankyo research exec points out “a lot of hype” around biomarkers

17-10-2011

Robert Beckman, executive director, clinical development oncology at Japanese drug major Daiichi Sankyo…

Daiichi SankyoOncologyPharmaceuticalResearch

Daiichi Sankyo admits supply problem with flu vaccine; gains approval for silodosin in China

23-09-2011

Japanese drug major Daiichi Sankyo (TYO: 4568) announced this week that its domestic subsidiary, Kitasato…

Asia-PacificDaiichi SankyoMarkets & MarketingOncologyPharmaceuticalRegulationsilodosinVaccines

Back to top